secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001104659-24-086529
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia Q2 net loss $27.9M; court rulings clear legal path for YUTREPIA approval
--------------------------------------------------------------------------------

- Q2 net loss $27.9M ($0.37/share) vs $23.5M ($0.36/share) in Q2 2023.
- Revenue from Sandoz promotion $3.7M, down from $4.8M due to lower sales volumes.
- Cash and equivalents $133.1M at June 30, 2024, up from $83.7M at Dec 31, 2023.
- Court denied UTHR's preliminary injunction on YUTREPIA patent '327 on May 31; D.C. court also denied TRO/PI against FDA.
- R&D expense fell 47% to $9.4M (no prior-year license fee); G&A rose 116% to $20.0M on sales force and legal costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465924086529/0001104659-24-086529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465924086529/tm2420885d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-086529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer